Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2/3 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

OTHER 9NIH 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 2Genitourinary 1

Conditions

Renal Pelvis and Ureter Urothelial Carcinoma 1Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 1Hodgkin Disease 1

Interventions

Specimen Handling 184Magnetic Resonance Spectroscopy 139Biopsy 102Immunoglobulin G 38Disulfides 38Cisplatin 37Nivolumab 36Platinum 35Paclitaxel 351,2-diaminocyclohexaneplatinum II citrate 35Radiation 34Cyclophosphamide 34Carboplatin 33Taxes 32Radiotherapy 28X-Rays 27pembrolizumab 26Doxorubicin 25Bevacizumab 24olaparib 22atezolizumab 21Gemcitabine 19Vincristine 18Prednisone 17Etoposide 17Leucovorin 16Cytarabine 16fludarabine 15durvalumab 15Phantoms, Imaging 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
NIH × Vinblastine × 30 days × Clear all
NCT04628767 2026-06-03

Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

National Cancer Institute (NCI)

Phase 2/3 Recruiting
131 enrolled
Genitourinary

Renal Pelvis and Ureter Urothelial Carcinoma

NCT05675410 2026-06-03

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

National Cancer Institute (NCI)

Phase 3 Recruiting
1,875 enrolled
Lymphoid

Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8

NCT03907488 2026-06-01

Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma

National Cancer Institute (NCI)

Phase 3 Active not recruiting
994 enrolled 11 charts 1 FDA
Lymphoid

Hodgkin Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡